Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
about
The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial HypertensionDirect role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications.Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis.Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments.Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertensionCyp2c44 gene disruption exacerbated pulmonary hypertension and heart failure in female but not male miceEffectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.Mineralocorticoid receptor: a critical player in vascular remodeling.30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature.Effects of low-dose tolvaptan on electrolyte abnormality and hemodynamic parameters in a liver cirrhosis-associated portopulmonary hypertension patient: A case report.Spironolactone in cardiovascular disease: an expanding universe?Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension.Role of hypoxia-induced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation.Introduction: Aldosterone and salt: heart and kidney.Autonomic nervous system involvement in pulmonary arterial hypertension.Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat.Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertensionNeurohormonal modulation as therapeutic avenue for right ventricular dysfunction in pulmonary artery hypertension: till the dawn, waitingVagal Nerve Stimulation for Pulmonary Hypertension: Some Promise, Some Skepticism
P2860
Q27013946-5A4ECAA9-F968-44DD-AAAF-501C8EE8AE15Q28085007-918212CE-5734-4537-9A2A-FDB677344212Q33631289-F33B6F02-DB4E-4D42-85F4-33A89BC87591Q33877343-74A2C627-4E2D-4BFA-B833-E79703763256Q34684861-DA25EBAF-ABE7-464A-8C97-BD0CD8173147Q35049443-5A7D54A4-5731-40FD-B195-FBADB719B70EQ36996364-FC6A1D34-B193-4FA6-9165-B98CBE5A3E98Q37248337-593476C5-4A7E-4D71-9E6D-05A0B70E8297Q37531525-44DDC8EF-63D4-42A2-9BE9-D643133A31E1Q37555431-5C1FBF85-DF2E-4C85-AA10-300039F441CFQ38109661-E320C60C-FC7F-4CEF-A8A1-67B1133116BBQ38238028-39185EE4-DA2A-40D3-9961-FCC04C44B590Q39386976-2A5ABD06-E652-4C99-9DAE-C03237CED974Q42329743-F6030526-C854-4F56-83F7-AFA2CF3935B2Q42364781-9AD12054-1EF3-4375-916A-A00A6A4AD3AEQ42370379-4930E090-9E20-4036-83B0-70D5EE286938Q42547773-B12E6292-13F0-4326-9B25-B6ADA7CB0D45Q44566109-6D221EB7-8F96-46C8-AB8A-239C79BF412BQ46183109-8CC26768-E8AC-4FA4-8076-6AFBB3C20DD1Q46273115-7FB9CE4C-B597-4571-A1FA-5365222EF666Q47647088-B6C5431A-A546-4423-85E5-D5FD7EFA961EQ53078828-E663B205-19EC-4C3C-AA9C-3F3361BC1BC8Q54263200-2972AFAB-8192-4E38-9E7C-81922B0489D0Q58704706-0A12CE3E-C424-4F38-B37A-E3054978EF37Q58804808-093564DC-DAA3-441D-897E-934B88C3F21EQ59136747-53687EFE-BF06-4796-8345-B14D69559511
P2860
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
@en
type
label
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
@en
prefLabel
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
@en
P2093
P2860
P1476
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
@en
P2093
Barry L Fanburg
Ioana R Preston
Iris Z Jaffe
Kristen D Sagliani
Nicholas S Hill
Rod R Warburton
P2860
P304
P356
10.1152/AJPLUNG.00300.2012
P577
2013-03-01T00:00:00Z